Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Wedbush Securities Inc.

Wedbush Securities Inc. lowered its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 21.8% in the second quarter, Holdings Channel reports. The institutional investor owned 14,530 shares of the biopharmaceutical company’s stock after selling 4,050 shares during the quarter. Wedbush Securities Inc.’s holdings in Dynavax Technologies were worth $163,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DVAX. Natixis Advisors L.P. increased its holdings in shares of Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 1,804 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Dynavax Technologies by 23.6% during the 4th quarter. BNP Paribas Financial Markets now owns 413,409 shares of the biopharmaceutical company’s stock worth $5,779,000 after buying an additional 78,824 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Dynavax Technologies by 7.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after buying an additional 293,337 shares during the last quarter. UBS Group AG increased its holdings in shares of Dynavax Technologies by 427.2% during the 4th quarter. UBS Group AG now owns 647,911 shares of the biopharmaceutical company’s stock worth $9,058,000 after buying an additional 525,012 shares during the last quarter. Finally, Trexquant Investment LP increased its holdings in shares of Dynavax Technologies by 51.3% during the 4th quarter. Trexquant Investment LP now owns 263,912 shares of the biopharmaceutical company’s stock worth $3,689,000 after buying an additional 89,521 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $11.17 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The stock has a market capitalization of $1.46 billion, a P/E ratio of 186.17 and a beta of 1.37. The company has a 50 day moving average price of $11.00 and a 200 day moving average price of $11.52. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The company had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. During the same quarter last year, the company posted $0.03 EPS. Equities research analysts forecast that Dynavax Technologies Co. will post 0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.